Humanigen — Investor Presentation (June 2020)
10 slides from Humanigen's investor presentation, Jun 16, 2020
Slide 1: Humanigen June 2020
0 Humanigen June 2020 “Part of the reason why some people get so severely ill... is what we call a Cytokine Storm... it’s actually the immune response that starts destroying your lungs and your tissue, and so if you can interrupt that immune response... you can avert some of the destructive effects
Slide 2: Disclaimer
1 Disclaimer The information contained in this document has been prepared solely for informational purposes and is not an offer to sell or p urchase or a solicitation of an offer to sell or purchase any interests or securities in Humanigen , Inc. This document may not be modified, reproduced, or red
Slide 3: Compassionate Use Program (CUP)
2 Compassionate Use Program (CUP) CUP conducted at Mayo Clinics, leading COVID - 19 expert centers with a choice of industry - wide research Under auspices of the hospital system COVID - 19 task force leader and senior physician Patient characteristics similar to intended Phase III entrants (Severe
Slide 4: Lenzilumab Cohort vs Remdesivir
3 Lenzilumab Cohort vs Remdesivir Lenzilumab patients had more comorbidities, similar oxygenation stats, but discharged much earlier Patient Baseline Characteristics; Days of Treatment 1 day Lenzilumab 5 day Remdesivir 10 day Remdesivir Median age (IQR) 65 (52 - 70) 61 (50 - 69) 62 (50 - 71) Male (%
Slide 5: Lenzilumab Cohort vs Other Therapies
4 Lenzilumab Cohort vs Other Therapies Lenzilumab patients were older, more comorbidities, similar oxygenation stats, but discharged much earlier Patient Baseline Characteristics Lenzilumab Remdesivir Lopinavir/Ritonavir Tocilizumab Mavrilimumab Median age (IRQ) 65 (52-70) 61 (50-69) 58 (50-68) 56.8
Slide 6: Lenzilumab: Faster Clinical Improvement
5 Lenzilumab: Faster Clinical Improvement Cumulative % incidence of clinical two point improvement Lenzilumab vs Remdesivir , Lopinavir, Mavrilimumab Lenzilumab patients improved faster and were discharged in half the time or faster 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% D
Slide 7: Oxygen Requirements Through Time
6 Oxygen Requirements Through Time SpO2/FiO2 ( Day - 1 vs last time point, p=0.00015) SpO2/FiO2 Ratio Full Lenzilumab: Improves Oxygenation
Slide 8: Lenzilumab: Improves Pyrexia and Inflammatory Markers
7 % of patients with 2 - Point Improvement Temperature (Day - 1 vs 3, p=0.0023) CRP ( Day - 1 vs Day 3, p=0.040) IL - 6 ( Day - 1 vs Day 3, p=0.035) Lenzilumab: Improves Pyrexia and Inflammatory Markers Note: statistical significance between mean temperature, CRP serum concentration, IL - 6 serum co
Slide 9: Lenzilumab: Improves Inflammatory Cytokines
8 Lenzilumab: Improves Inflammatory Cytokines Note: statistical significance between mean temperature, CRP serum concentration, IL - 6 serum concentration, and absolute lymphoc yte counts on day - 1 versus day 3 post - lenzilumab was investigated using a two - tailed paired t - test. Day 3 was deter
Slide 10: Lenzilumab: Improves Key Hematologic Indices
9 Absolute Lymphocyte Counts ( Day - 1 vs last value, p=0.017) Platelets ( Day - 1 vs Day 3, p=0.001) Absolute Neutrophil Counts Lenzilumab: Improves Key Hematologic Indices p=0.017 p=0.017 p=0.001 Absolute Lymphocyte Counts ( Day - 1 vs last value, p=0.017)